Belay Diagnostics Launches Summit™ for CNS Cancer Testing
Belay Diagnostics, a pioneering laboratory known for its focus on molecular diagnostics for central nervous system (CNS) cancers, has made a significant advancement with the introduction of its Summit™ assay. This groundbreaking cerebrospinal fluid (CSF) testing method aims at enhancing the detection and management of CNS cancers.
Transforming Cancer Testing
The Summit™ test is engineered to analyze DNA variants found in CSF, which serves as a critical fluid in diagnosing CNS cancers. By utilizing cutting-edge technology, this assay empowers oncologists to make informed decisions tailored to each patient's unique situation.
Key Features of the Summit™ Assay
The Summit™ utilizes a proprietary technique known as MethylSaferSeqS. This advanced duplex sequencing method is capable of capturing minute fragments of tumor DNA that are shed into the CSF, offering valuable insights into the tumor's genetic profile. With the ability to work with as little as 20ng of tumor DNA, this test places high accuracy at the forefront of CNS cancer diagnostics.
Impressive Validation Results
The efficacy of the Summit™ test has been validated through rigorous clinical studies involving 124 patients diagnosed with various CNS cancers. This extensive validation included examples from both primary and metastatic sources, covering a variety of common and rare oncological pathologies, such as glioblastomas and breast cancer metastases. The performance results revealed 90% sensitivity and 95% specificity when comparing test results with biopsy-derived alterations.
Commitment to Patient Care
Brian Coe, Co-founder and CEO of Belay Diagnostics, expressed his gratitude for the chance to serve patients through this innovative testing option. He acknowledged the tremendous efforts of his team and collaborators in bringing this critical tool to market, emphasizing their shared commitment to enhancing patient outcomes.
Advancing Therapeutic Options
The introduction of the Summit™ assay complements Belay's existing portfolio of advanced liquid biopsy tests. These tools are specifically designed to support clinicians in making informed decisions regarding therapeutic options and clinical trial opportunities for patients with CNS tumors. With a mission to transform the treatment landscape, Belay Diagnostics continues to focus on technological advancements that improve patient care and diagnostics.
About Belay Diagnostics
Belay Diagnostics is dedicated to advancing diagnostic technologies that change the trajectory for patients dealing with CNS cancers. With its Summit™ and Vantage™ assays, the company seeks to illuminate pathways to effective treatment and patient support. Their relentless commitment revolves around enhancing the quality of life for those affected by CNS tumors.
Frequently Asked Questions
What is the Summit™ assay?
The Summit™ assay is a CSF liquid biopsy test that helps detect DNA variants associated with CNS cancers.
How does the Summit™ test work?
It analyzes trace fragments of tumor DNA found in cerebrospinal fluid to provide insights into tumor genetics.
What were the validation results for the Summit™ test?
The test demonstrated 90% sensitivity and 95% specificity in detecting DNA variants in CNS cancers.
Who developed the Summit™ assay?
The Summit™ assay was developed by Belay Diagnostics, a laboratory specializing in CNS cancer diagnostics.
What is the mission of Belay Diagnostics?
Belay Diagnostics aims to transform the CNS cancer journey through innovative diagnostic technologies and patient care support.
